Silverback Therapeutics, Inc.

Sean Wesley Smith

Peter Robert Baum

Craig Alan Coburn

Brenda L Stevens

Philip Tan

Valerie Odegard

Robert Dubose

Peter A Thompson

The disclosure provides conjugates of anti-ASGR1 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating liver viral infections with the conjugates. The disclosure also provides for anti-ASGR1 antibodies or antigen binding fragments thereof and methods for using the antibodies or antigen binding fragments thereof in treating liver viral infections.

Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof

Benzazepine compounds, conjugates, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed benzazepine compounds are useful, among other things, in the treating of cancer and modulating TLR8. Additionally, benzazepine compounds incorporated into a conjugate with an antibody construct are described herein.

Benzazepine compounds, conjugates, and uses thereof

Growing community of inventors

Seattle, WA, United States of America

Sean Wesley Smith